Clovis Oncology Inc. (NASDAQ:CLVS) does about 4.58M shares in volume on a normal day but saw 4198388 shares change hands in Tuesday trading. The company now has a market cap of 439.41M USD and an enterprise value of about $814.05M. Its current market price is $5.06, marking a decrease of -2.88% compared to the previous close of $5.21. The 52 week high reached by this stock is $17.37 whilst the lowest price level in 52 weeks is $2.93. The script in recent trading has seen the stock touch a high of $5.23 and a low of $4.99.
Clovis Oncology Inc. (CLVS) has a 20-day trading average at $5.32 and the current price is -70.87% off the 52-week high compared with 72.70% distance from its 52-week low. The 50-day simple moving average of the closing price is $6.04 and its 200-day simple moving average is $7.86. If we look at the stock’s price movements over the week, volatility stands at 6.03%, which increases to 7.26% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 40.73 to suggest the stock is neutral.
8 analysts observing the Clovis Oncology Inc. (CLVS) stock have set the 12-month price targets for the company’s shares at between $4.00 and $23.00. The median price target is 15.67% away from the current levels at $6.00.
FactSet Research has provided data showing that 8 brokerages have issued ratings for the stock. 2 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 4 have advised that investors hold their positions. The consensus recommendation rating is Hold and Wall Street’s advice is for investors to Hold the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 18, 2020 when H.C. Wainwright reiterated the stock to “Buy” and issued a price target of between $29 and $33. SVB Leerink downgraded the stock to “Underperform” from Mkt Perform on April 27, 2020 at a price target of $5. BofA/Merrill downgraded its price target at $6.
The current price level is -5.91%, -16.87%, and -35.66% away from its SMA20, SMA50, and SMA200 respectively, with the CLVS price moving above the 50-day SMA on September 01. Clovis Oncology Inc. (CLVS) stock is down -0.59% over the week and -17.59% over the past month. Its price is -51.46% year-to-date and -2.32% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$1.15 below consensus estimates by -$0.11. The company’s next earnings report is expected on 10/28/2020, with forecasts estimating quarterly EPS at -$1 and -$4.32 for whole year. CLVS’s earnings per share are forecast to grow by 41.90% this year and 41.20% over next year. Expected sales for next quarter are $48.89 million, which analysts say will come at $175.45 million for the current fiscal year and next year at $240.89 million. In addition, estimates put the company’s current quarterly revenue at an average of $43.85 million.
Its 12-month price target is $6.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $4.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $23.00.
Outstanding shares total 88.20M with insiders holding 2.27% of the shares and institutional holders owning 48.46% of the company’s common stock. The company has a return on investment of -76.50% and return on equity of 316.90%. The beta has a value of 2.25. Price to sales ratio is 2.76.
According to a U.S. Securities and Exchange Commission filing, SPDR S&P Biotech ETF has reduced its position in Clovis Oncology Inc. (CLVS) to 8,591,805 shares, mirroring a recent drop by -0.99%. SPDR S&P Biotech ETF dumped 86079.0 shares of Clovis Oncology Inc. common stock bringing its total worth to about $49.75 million at the end of recent close, SEC documents show. SPDR S&P Biotech ETF isn’t the only investment manager who changed stakes and is followed by Vanguard Total Stock Market Index, which added 762.0 shares to end up with 2,415,365 shares worth $13.98 million. iShares Russell 2000 ETF cut their holdings by -4.46% in the company over the course of the most recent quarter. It now holds a 1.68% position in Clovis Oncology Inc. thanks to 1.48 million shares amounting to $8.56 million.